KKR Income Opportunities Fund
Change company Symbol lookup
Select an option...
KIO KKR Income Opportunities Fund
BOAS BOA Acquisition Corp
ESBA Empire State Realty OP LP
ASGN ASGN Inc
CMS CMS Energy Corp
POWRU Powered Brands
VLDRW Velodyne Lidar Equity Warrants Exp 29 Sep 2025 *W EXP 09/29/2025
JPM JPMorgan Chase & Co
UVV Universal Corp
LNC Lincoln National Corp
Go

Company profile

KKR Income Opportunities Fund (Fund) is a closed-end registered management investment company. The Fund’s primary investment objective is to seek a high level of current income with a secondary objective of capital appreciation. The fund is primarily engaged in investing targeted portfolio of loans and fixed-income instruments (including derivatives) of United States and non-United States issuers and implementing hedging strategies in order to seek to achieve attractive risk-adjusted returns. The Fund invests at least 80% of its Managed Assets in loans and fixed-income instruments or other instruments, including derivative instruments. The Fund's investment advisor is KKR Credit Advisors (US) LLC.

Closing Price
$15.71
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
0

10-day average volume:
70,178
0

BioHarvest Sciences Appoints Astronaut Chris Hadfield to the Board of Advisors

9:53 am ET December 1, 2021 (PR Newswire) Print

Hadfield's expertise will lead BioHarvest's expanded focus to include space biology

BioHarvest Sciences Inc. ("BioHarvest" or the "Company") (CSE: BHSC) has appointed renowned astronaut Chris Hadfield to its board of advisors as part of a drive to leverage its biotech technology platform to provide essential nutrition and active ingredients for space exploration and potential new settlements in space.

https://mma.prnewswire.com/media/1699683/BioHarvest_Sciences_Inc_Astronaut_and_engineer_Chris_Hadfield.jpg

Hadfield brings 40 years of scientific experience to the Canadian-Israeli biotech firm, which has developed and patented a plant bio-cell technology, called BioFarming, capable of growing the active and beneficial plant based ingredients at industrial scale, without the need to grow the plant itself.

"Chris's unparalleled experience will help marry our plant cellular biology expertise with space science," said BioHarvest CEO Ilan Sobel. "He is a great addition to our advisory board at this phase of our growth, and he'll help us in our drive to be a global biotech leader."

BioHarvest's BioFarming technology has the potential to efficiently produce primary metabolites such as premium proteins that are needed to provide required nutrition for humans to live in space. It can also produce antioxidant compounds with antioxidant activity that can help reduce human cellular stress and prevent damage caused by microgravity and ionizing radiation, which is a critical health challenge experienced by astronauts while in space.

Hadfield joined the BioHarvest board of advisors a few weeks after visiting the Company's research and development laboratories in Rehovot, Israel.

"BioHarvest's proprietary platform technology has the potential to make a significant impact on the world as well as in bio-space science," Hadfield said. "The company has built a world-class team of scientists, and I look forward to working with them, with my fellow advisors, to scale BioHarvest's solution."

The Canadian-born reserve colonel is an astronaut, engineer, and RCAF pilot who has flown 3 space missions, done 2 spacewalks, and commanded the International Space Station. He was named the top test pilot in both the US Air Force and the US Navy, and served as NASA's Director of Operations in Russia.

Hadfield is an adjunct professor at the University of Waterloo, an adviser to SpaceX and Virgin Galactic, and chair of the board of the Open Lunar Foundation. He also leads the Space stream at the Creative Destruction Lab tech incubator, and is co-creator and host of TV series on BBC and National Geographic, as well as a 4-time internationally best-selling author.

BioHarvest, which can produce red grape, olive, and pomegranate cells, recently announced that it has successfully grown coral-shaped clusters of Cannabis trichomes in bioreactors as well (see news release dated August 19 and September 1, 2021). The company recently announced revenues of USD 688K in the third quarter of 2021, representing 44% growth over the previous quarter, based on promising early demand of its flagship red grape-based VINIA(R) product (see news release dated October 5, 2021).

About BioHarvest Sciences Inc.

BioHarvest Sciences Inc. (CSE: BHSC) is a fast-growing Biotech firm listed on the Canadian Securities Exchange. BioHarvest has developed a patented bio-cell growth platform technology capable of growing the active and beneficial ingredients in fruit and plants, at industrial scale, without the need to grow the plant itself. This technology is economical, ensures consistency, and avoids the negative environmental impacts associated with traditional agriculture. BioHarvest is currently focused on nutraceuticals and the medicinal cannabis markets. Visit: www.bioharvest.com.

BioHarvest Sciences Inc.Ilan Sobel, Chief Executive Officer

For further information, please contact:Dave Ryan, VP Investor Relations & DirectorPhone: 1 (604) 622-1186Email: dave@bioharvest.com

Twitter | Facebook | LinkedIn | YouTube

Forward-Looking Statements

Information set forth in this news release might include forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. There is no assurance that we will achieve our objective of making our products available in multiple markets including bio-space and exposing our technology to different verticals. In particular, there is no assurance that the Company will be able to leverage its technology platform to successfully provide essential nutrition and active ingredients for space exploration. There is no assurance that the Company will be successful in expanding its technology to broader medical applications or conduct clinical trials to validate the efficacy of the Company's products for new forms of medical treatments. Clinical trials are subject to risks of significant cost overruns and lengthy delays with no assurance they will confirm desired results. Even where desired results are obtained government approvals for treatments take considerable time and cannot be guaranteed. There is no assurance the BioFarming technology will make a significant impact on multiple verticals of life -science based businesses in general or in the bio-space industry. There is no assurance that we will achieve our objective of being a leading supplier of Cannabis. Delays and cost overruns may result in delays achieving our objectives obtaining market acceptance and regulatory approvals for geographic expansion is subject to risk and cannot be guaranteed. Projected sales of Cannabis will require the company to obtain production and / or export licensing which cannot be assured.

All forward-looking statements are inherently uncertain, and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHSC does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.

Neither the Canadian Securities Exchange nor its Regulation Services Provider accept responsibility for the adequacy or accuracy of this release.

https://mma.prnewswire.com/media/1699761/BioHarvest_Sciences_Inc_Logo.jpg

https://c212.net/c/img/favicon.png?sn=NY92350&sd=2021-12-01

View original content to download multimedia:https://www.prnewswire.com/news-releases/bioharvest-sciences-appoints-astronaut-chris-hadfield-to-the-board-of-advisors-301434610.html

SOURCE BioHarvest Sciences Inc.

https://rt.prnewswire.com/rt.gif?NewsItemId=NY92350&Transmission_Id=202112010700PR_NEWS_USPR_____NY92350&DateId=20211201

comtex tracking

COMTEX_398088555/1005/2021-12-01T09:53:17

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.